News

Clinicians are aware of established guidelines for post-treatment surveillance and follow-up of people who have been treated for cancer. But what do patients expect?

Lynparza tablets (olaparib) tablets were granted FDA approval as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

Artist Ryan Berardi’s work goes way beyond pretty pictures. In fact, his 3D animations of what can go wrong during chemotherapy paint a horrific scene.

Bladder cancer is uncommon, and is more often diagnosed at an advanced stage because it has symptoms that mimic other disorders.

Physical activity may be effective in mitigating cancer-related cognitive impairment. Prior studies show this may be a promising treatment. However, sample sizes were small and self-reported measures varied.

The novel combination of a neurokinin-1 (NK-1) receptor antagonist and the 5-HT3 receptor antagonist palonosetron (Aloxi), NEPA (Akynzeo) had non-inferior efficacy compared to a conventional aprepitant regimen for preventing chemotherapy-inducted nausea and vomiting (CINV).

The FDA has approved CPX-351 (Vyxeos), a fixed-combination of daunorubicin and cytarabine, for adult patients with either newly-diagnosed therapy-related acute myeloid leukemia (t-AML) ot AML with myelodysplasia-related changes (AML-MRC).

Ibrutinib has been approved for the treatment of adult patients with chronic graft versus hose disease (GVHD) following the failure of 1 or more lines of systemic therapy.

The FDA has approved enasidenib for patients with IDH2-Mutated acute myeloid leukemia (AML).

CD19 CAR T-cell therapy induced a high-response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia (CLL).

The FDA has granted accelerated approval to nivolumab (Opdivo) for the treatment of adult and pediatric patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

A recent study has found that there may be no risk of increasing skin irritation by using antiperspirants for patients with breast cancer undergoing radiation.

A side-effect of some lung cancer treatments is turning some patient's gray hair darker again.

A 15-year brain tumor survivor offers advice and discusses the advances that have been made since his diagnosis.

Checkpoint inhibitors against PD-1 and PD-L1 have shown promise, both as monotherapies and in combination with chemotherapy for patients with triple-negative breast cancer (TNBC).

Oncology Nursing News spoke with an expert about coping strategies for those who have developed chemotherapy-induced peripheral neuropathy (CIPN).

For years, people believed that there was a link between vasectomies and prostate cancer.

A recent study found that women with breast cancer often have a network of people that they consult to help them make treatment decisions.

Rami Komrokji, MD, discusses the advances that have been made in myelodysplastic syndrome MDS in the past few years, as well as the MDS Clinical Research Consortium and its importance.

Ovarian cancer expert, David M. Gershenson, MD, from University of Texas MD Anderson Cancer Center discusses three treatments for some of the rare types of ovarian cancers and the challenges to treating these diseases.

Breast cancer expert Joyce O'Shaughnessy, MD, discusses the current treatments for metastatic triple negative breast cancer (TNBC) as well as potential options in the future.

The FDA has approved ipilimumab (Yervoy) for the treatment of patients aged ≥ 12 years with unresectable or metastatic melanoma.

Researchers at Mayo Clinic evaluated the use of secreted proteins as markers of pancreatic ductal adenocarcinoma.

“If you locked everybody in a room for a week, I think we could come up with something that everybody would be comfortable with,” said Blase Polite, MD, a co-author of the statement, and immediate past chair of ASCO’s government relations committee.

Ovarian cancer screening for women who do not have symptoms of the disease may do more harm than good, according to the USPSTF.

How patients can be their own advocates and maximize their care team appointments by speaking up and asking questions.

Currently, myleproliferative neopasms are not on the Vereran's Health Administration presumptive list but MPN Advocacy and Education International is working to change that.

Karley Trautman, DNP, ANP-BC, explains her efforts to improve the rates of venous thromboembolism (VTE), as well as the rates of recurrence of VTE in the Blood Cancer and Bone Marrow Transplant program of University of Colorado Hospital.